NCT04370834 2025-02-04Tocilizumab for Patients With Cancer and COVID-19 DiseaseNational Cancer Institute (NCI)Phase 2 Terminated1 enrolled 10 charts
NCT01441063 2020-10-27Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseNational Institutes of Health Clinical Center (CC)Phase 2 Completed8 enrolled 18 charts